



Current Guidelines for the Management of Asthma

Bimal Roy Krishna Touro University, USA.



Abstract

Asthma is considered to be primarily an inflammatory disorder with secondary bronchoconstriction. Patient manifestations usually are shortness of breath, wheezing, cough and chest tightness. The intensity may vary over time and become exacerbated with external factors that further irritate the airway.

While bronchial hyperactivity and airway inflammation may likely be present they are not the only factors that determine diagnosis. Identification of external and other factors that exacerbate asthma is crucial and smoking is also a modifiable factor. High risk patients including geriatric and pediatric patients may require more aggressive treatment. The long term goals of management are to achieve long term symptomatic relief which may include the use of prophylactic agents. Management of asthma initially supported the use of a short acting bronchodilator and prophylactic management where deemed necessary. The categories of asthma medications include controller, reliever, prophylactic and add-on medications. Effective 2019 the GINA guidelines no longer support the use of short acting bronchodilators as preferred initial therapy. Preferential therapy now favors the use of inhaled corticosteroids with a short acting bronchodilator. A step-up approach is initiated when necessary, which includes adjustment inhaled corticosteroids dosage of bronchodilators and eventually to include adjunct medications and monoclonal.

This presentation outlines the pathogenesis of asthma, patient presentation and diagnosis and current treatment guidelines



Biography:

Dr. Krishna is currently Professor and Director of Pharmacology at the College of Osteopathic Medicine, Touro University in Nevada. He obtained a Bachelor of Science (First Class Honors) in Pharmacology and Physiology and a Doctor of Philosophy, Medicine (OB/GYN/Pharmacology) from Monash University in Australia. Dr. Krishna also teaches for the Step 1 USMLE and COMLEX reviews for Kaplan Medical throughout the United States and in UAE, Europe, Saudi Arabia, India, Mexico and the Caribbean. He has been teaching online for Kaplan University for over 7 years and is the contributing author for Kaplan Medical's Pharmacology Review Book. He has contributed to numerous publications and is a member of a number of organizations including Fellow-American College of Clinical Pharmacology

Speaker Publications:

- 1. Medication-induced osteoporosis: screening and treatment strategies. Ther Adv Musculoskelet Dis. 2014 Oct; 6(5): 185–202.
- 2. Drug-induced Bone Loss: A Major Safety Concern in Europe. Expert Opinion in Drug Safety. 2018, Oct;17. (10).1005-1014.
- 3. Osteoporosis Screening, Diagnosis, and Treatment Guideline. Kaiser Permanente. 2019.



Vol.8 No.4

4.Pharmacological Management of Osteoporosis in Postmenopausal Women Guideline Resources. The Journal of 5 5. Clinical Endocrinology & Metabolism, Volume 105, Issue 3, March 2020, Page 584-594.

6.Osteoporosis Treatment: An Evidence-Based Approach. Kelly R. Ragucci, Sarah P. Shrader.Journal of Gerontological Nursing. 2011;37(7):17-22.

<u>30th Annual European Pharma Congress</u>; Berlin, Germany- May 18-19, 2020.

Abstract Citation:

Bimal Roy Krishna, Current Guidelines for the Management of Asthma, Pharma Europe 2020, 30th Annual European Pharma Congress; Berlin, Germany- May 18-19,2020

(https://europe.pharmaceuticalconferences.com/abstract/2 020/current-guidelines-for-the-management-of-asthma